Eton Pharmaceuticals has relaunched HEMANGEOL, the only FDA-approved treatment for infantile hemangiomas, a type of non-cancerous tumor that can appear on infants shortly after birth. This medication is now available exclusively through Anovo Specialty Pharmacy, which aims to make it easier for families to access this critical treatment. The company has also introduced Eton Cares, a patient support program that offers $0 co-pay for eligible patients and enhanced assistance for families navigating this challenging diagnosis.

For parents of infants with hemangiomas, timely treatment is vital. Early intervention can significantly improve outcomes, preventing complications and ensuring the best possible cosmetic results. It is estimated that between 5,000 and 10,000 infants in the United States receive HEMANGEOL each year. The treatment is typically started between five weeks and five months of age and lasts about six months. This early window is crucial, as untreated hemangiomas can grow rapidly and lead to serious health issues.

The relaunch of HEMANGEOL comes with a focus on streamlining access to care, which is essential given the urgency of treatment. While the medication has a solid foundation as an FDA-approved therapy, it is important for families to consult healthcare professionals for guidance on initiating treatment. The integration of patient support services aims to alleviate some of the stress that comes with managing a rare disease in infants, ensuring families have the resources they need during this critical time.

Source: globenewswire.com